Alastair smith, chief executive of Avacta Group Plc's (LON:AVCT), tells Proactive that interest in their Affimer technology continues to grow following the announcement of another collaboration agreement - this time with OncoSec Medical Inc (NASDAQ:ONCS).
OncoSec has developed a gene delivery technology called ImmunoPulse which it wants to use to deliver Affimers - including Avacta's PD-L1 inhibitor - into tumour cells and other tissues.
The companies plan to then demonstrate efficacy of the Affimers in a relevant in vivo tumour model.
Meet Netscientific PLC, discoverIE Group plc, Itaconix Plc and Realm Therapeutics plc at our event, London, 25 January 2018.Register here >>